Based on 8 Wall Street analysts offering 12 month price targets for ChemoCentryx in the last 3 months. The average price target is €48.17 with a high forecast of €48.17 and a low forecast of €48.17. The average price target represents a ― change from the last price of ―.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"14":"€14","33":"€33","52":"€52","23.5":"€23.5","42.5":"€42.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":48.165,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">€48.16</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48.165,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">€48.16</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":48.165,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">€48.16</span>\n  </div></div>","useHTML":true}}],"tickPositions":[14,23.5,33,42.5,52],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jan<br/>2022","6":"Apr<br/>2022","9":"Jul<br/>2022","12":"Oct<br/>2022","25":"Oct<br/>2023"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,51.94,51.64961538461538,51.35923076923077,51.06884615384615,50.778461538461535,50.488076923076925,50.19769230769231,49.90730769230769,49.61692307692307,49.32653846153846,49.036153846153844,48.74576923076923,48.45538461538462,{"y":48.165,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,51.94,51.64961538461538,51.35923076923077,51.06884615384615,50.778461538461535,50.488076923076925,50.19769230769231,49.90730769230769,49.61692307692307,49.32653846153846,49.036153846153844,48.74576923076923,48.45538461538462,{"y":48.165,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,51.94,51.64961538461538,51.35923076923077,51.06884615384615,50.778461538461535,50.488076923076925,50.19769230769231,49.90730769230769,49.61692307692307,49.32653846153846,49.036153846153844,48.74576923076923,48.45538461538462,{"y":48.165,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":28.58,"date":1635465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.52,"date":1636070400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32.27,"date":1638489600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":32,"date":1641513600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.39,"date":1643932800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.74,"date":1646352000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.295,"date":1648771200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.684,"date":1651795200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.055,"date":1654214400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.04,"date":1656633600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.5,"date":1659657600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":50.29,"date":1662076800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":51.94,"date":1665100800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€48.17

Average Price Target€48.17

Lowest Price Target€48.17

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Dae Gon Ha

Stifel Nicolaus

€48.16

Hold

―

Downgraded

08/10/22

Benzingas Top Ratings Upgrades, Downgrades For August 10, 2022For ChemoCentryx Inc CCXI , Stifel downgraded the previous rating of Buy to Hold. In the second quarter, ChemoCentryx showed an EPS of $0.44, compared to $0.56 from the year-ago quarter. At the moment, the stock has a 52-week-high of $50.94 and a 52-week-low of $14.95. ChemoCentryx closed at $50.79 at the end of the last trading period.

Edward White

H.C. Wainwright

€48.16

Hold

―

Reiterated

08/09/22

Analysts Offer Insights on Healthcare Companies: ChemoCentryx (NASDAQ: CCXI) and ATI Physical Therapy (NYSE: ATIP)

Anupam Rama

J.P. Morgan

€48.16

Hold

―

Reiterated

08/08/22

Analysts' Opinions Are Mixed on These Healthcare Stocks: BioCryst (NASDAQ: BCRX), ChemoCentryx (NASDAQ: CCXI) and Heska (NASDAQ: HSKA)

Edward Nash

Canaccord Genuity

€48.16

Hold

―

Downgraded

08/05/22

Canaccord Genuity downgrades ChemoCentryx (CCXI) to HoldCanaccord Genuity analyst Ed Nash downgraded ChemoCentryx (NASDAQ: CCXI) from Buy to Hold with a price target of $52.00.

Joseph Schwartz

SVB Securities

€48.16

Hold

―

Downgraded

08/05/22

SVB Leerink Downgrades ChemoCentryx to Market Perform, Lowers Price Target to $52

Edward Tenthoff

Piper Sandler

€48.16

Hold

―

Downgraded

08/04/22

ChemoCentryx (CCXI) downgraded to Neutral from Overweight at Piper SandlerPiper Sandler analyst Edward Tenthoff downgraded ChemoCentryx to Neutral from Overweight with a $52 price target after Amgen (AMGN) announced its intention to acquire the company for $4B or $52.00 per share in cash. The analyst cites the pending takeover for the downgrade.

Steven Seedhouse

Raymond James

―

Hold

―

Downgraded

08/04/22

Raymond James Downgrades ChemoCentryx to Market Perform

Unknown Analyst

Not Ranked

Wells Fargo

€48.16

Hold

―

Downgraded

08/04/22

Wells Fargo downgrades ChemoCentryx (CCXI) to Equal WeightWells Fargo downgraded ChemoCentryx (NASDAQ: CCXI) from Overweight to Equal Weight with a price target of $52.00.

2CX Analyst Recommendation Trends

Currently, no data available

Please return soon. This page is being updated.

Each month's total comprises the sum of three months' worth of ratings.

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxxxxxxxxxxxxxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

2CX Financial Forecast

No data currently available

2CX Earnings Forecast

Currently, no earnings data available.

No data currently available

2CX Sales Forecast

Currently, no sales data available.

2CX Stock Forecast FAQ

What is DE:2CX’s average 12-month price target, according to analysts?

Based on analyst ratings, Chemocentryx Inc.’s 12-month average price target is €48.17.

What is DE:2CX’s upside potential, based on the analysts’ average price target?

Currently there's no upside potential for DE:2CX, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Chemocentryx Inc. a Buy, Sell or Hold?

Chemocentryx Inc. has a conensus rating of Hold, which is based on 0 buy ratings, 8 hold ratings and 0 sell ratings.

What is Chemocentryx Inc.’s share price target?

The average share price target for Chemocentryx Inc. is €48.17. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €48.17 ,and the lowest forecast is €48.17. The average share price target represents N/A Increase from the current price of N/A.

What do analysts say about Chemocentryx Inc.?

Chemocentryx Inc.’s analyst rating consensus is a Hold. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of Chemocentryx Inc.?

To buy shares of DE:2CX, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

ChemoCentryx (2CX) Stock Forecast & Price Target

2CX Analyst Ratings

2CX Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

2CX Analyst Recommendation Trends

2CX Financial Forecast

2CX Earnings Forecast

2CX Sales Forecast

2CX Stock Forecast FAQ

Get More with TipRanks Premium

Detailed List of Analyst Forecasts